Asset Management One Co. Ltd. Boosts Stake in Boston Scientific Co. (NYSE:BSX)

Asset Management One Co. Ltd. boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 696,124 shares of the medical equipment provider’s stock after acquiring an additional 53,471 shares during the period. Asset Management One Co. Ltd.’s holdings in Boston Scientific were worth $63,090,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Creative Planning increased its holdings in shares of Boston Scientific by 7.7% in the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock valued at $17,113,000 after purchasing an additional 14,663 shares during the last quarter. NBC Securities Inc. raised its holdings in shares of Boston Scientific by 20.5% during the 3rd quarter. NBC Securities Inc. now owns 11,761 shares of the medical equipment provider’s stock worth $985,000 after acquiring an additional 2,001 shares during the period. Wolff Wiese Magana LLC boosted its position in shares of Boston Scientific by 7,262.5% during the 3rd quarter. Wolff Wiese Magana LLC now owns 2,945 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 2,905 shares during the last quarter. AAFMAA Wealth Management & Trust LLC grew its holdings in shares of Boston Scientific by 10.4% in the third quarter. AAFMAA Wealth Management & Trust LLC now owns 32,732 shares of the medical equipment provider’s stock valued at $2,743,000 after purchasing an additional 3,077 shares during the period. Finally, Summit Investment Advisory Services LLC acquired a new stake in Boston Scientific during the third quarter worth about $212,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.4 %

Shares of NYSE BSX opened at $106.16 on Friday. Boston Scientific Co. has a 12-month low of $65.00 and a 12-month high of $107.17. The stock has a market cap of $156.47 billion, a P/E ratio of 84.93, a PEG ratio of 2.79 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The business’s fifty day simple moving average is $95.80 and its 200-day simple moving average is $87.85.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities analysts predict that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BSX. TD Cowen boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Morgan Stanley increased their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Raymond James upped their price target on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research note on Thursday, February 6th. Finally, Mizuho raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus target price of $107.39.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 6,389 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $105.06, for a total transaction of $671,228.34. Following the completion of the transaction, the executive vice president now directly owns 24,293 shares of the company’s stock, valued at approximately $2,552,222.58. This represents a 20.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 87,326 shares of company stock worth $8,673,948 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.